Generic Name and Formulations:
Leuprolide acetate 7.5mg; depot susp for IM inj.
Company:
AbbVie
Palliative treatment of advanced prostatic carcinoma.
7.5mg IM once a month. Rotate inj site.
Not applicable.
GnRH analogue.
Women. Pregnancy (Cat.X).
Metastatic vertebral lesions. Urinary obstruction. Monitor serum testosterone, PSA, acid phosphatase. Increased risk of diabetes, MI, sudden cardiac death, stroke; monitor blood glucose, HbA1c, and for signs/symptoms of CVD during therapy. Risk of QT prolongation: long-term androgen deprivation therapy, congenital long QT syndrome, electrolyte abnormalities, or CHF, and concomitant Class IA or III antiarrhythmics. Instruct patient on correct self administration.
Concomitant Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmics may prolong the QT interval.
Hot flashes/sweats, inj site reaction, initial worsening of signs/symptoms (eg, bone pain, urinary tract obstruction, hematuria), edema, GI upset, pain, cardiovascular events, CNS and antiandrogenic effects, asthenia, spinal cord compression; hyperglycemia, anaphylactoid, photosensitivity.
Depot kit—1 (prefilled dual-chamber syringe w. supplies)